Cargando…

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report

The prognosis of leptomeningeal dissemination of recurrent glioblastoma is poor, and chemotherapy results in minimal palliative efficacy. Temozolomide (TMZ) is an established therapy for patients with malignant glioma and the standard of care in parenchymal gliomas; however, few reports have been pu...

Descripción completa

Detalles Bibliográficos
Autores principales:	OKITA, YOSHIKO, NONAKA, MASAHIRO, UMEHARA, TORU, KANEMURA, YONEHIRO, KODAMA, YOSHINORI, MANO, MASAYUKI, NAKAJIMA, SHIN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356381/ https://www.ncbi.nlm.nih.gov/pubmed/25789061 http://dx.doi.org/10.3892/ol.2015.2940

Ejemplares similares

MPC-04 MOLECULAR FEATURES AND CLINICAL OUTCOMES OF ELDERLY GLIOBLASTOMA PATIENTS: ANALYSES OF KANSAI NETWORK AND TCGA COHORTS
por: Fukai, Junya, et al.
Publicado: (2019)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

NI-02 THE ASSOCIATION BETWEEN (11)C-METHIONINE UPTAKE, IDH GENE MUTATION, AND MGMT PROMOTER METHYLATION IN PATIENTS WITH GRADE II AND III GLIOMAS
por: Okita, Yoshiko, et al.
Publicado: (2019)

Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts
por: Umehara, Toru, et al.
Publicado: (2019)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

Ipsilateral hemiparesis caused by putaminal hemorrhage in a patient with horizontal gaze palsy with progressive scoliosis: a case report
por: Yamada, Shuhei, et al.
Publicado: (2015)

Infrequent RAS mutation is not associated with specific histological phenotype in gliomas
por: Makino, Yasuhide, et al.
Publicado: (2021)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

NI-13 The effectiveness and limitation of survival prediction in primary glioblastoma using machine learning-based texture analysis
por: Umehara, Toru, et al.
Publicado: (2020)

Response of Leptomeningeal Dissemination of Anaplastic Glioma to Temozolomide: Experience of Two Cases
por: Bae, Jin Woo, et al.
Publicado: (2017)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

NI-13 PREDICTION OF PROGNOSIS IN NEWLY DIAGNOSED GLIOBLASTOMA USING MACHINE LEARNING-BASED TEXTURE ANALYSIS OF PREOPERATIVE MRI
por: Umehara, Toru, et al.
Publicado: (2019)

Glioblastoma Multiforme in the Pineal Region with Leptomeningeal Dissemination and Lumbar Metastasis
por: Matsuda, Ryosuke, et al.
Publicado: (2015)

TB-8 Genetic and molecular properties of long-term proliferating tumorsphere -forming glioma derived cells
por: Kijima, Noriyuki, et al.
Publicado: (2021)

Surgical Treatment of Brain Metastasis of Extramammary Paget’s Disease: A Case Report
por: Miura, Shimpei, et al.
Publicado: (2020)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
por: Arita, Hideyuki, et al.
Publicado: (2018)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination
por: You, Hye Jin, et al.
Publicado: (2016)

Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma
por: MATSUDA, Kenichiro, et al.
Publicado: (2022)

IM-7 Identification of novel glioblastoma specific antigen using patient derived tumor cell for CAR-T cell therapy
por: Nakagawa, Tomoyoshi, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors
por: Sasaki, Takahiro, et al.
Publicado: (2018)

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
por: Lu, Guangrong, et al.
Publicado: (2019)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Pineocytoma with diffuse dissemination to the leptomeninges
por: Gomez, Caitlin, et al.
Publicado: (2011)

Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
por: Kaloshi, Gentian, et al.
Publicado: (2014)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
por: Darmon, Ilan, et al.
Publicado: (2017)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients
por: Battista, Francesca, et al.
Publicado: (2022)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network
por: Fukuma, Ryohei, et al.
Publicado: (2019)

Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma
por: Narita, Yoshitaka, et al.
Publicado: (2022)

Leptomeningeal Dissemination of a Low-Grade Brainstem Glioma without Local Recurrence
por: Moon, Jung-Ho, et al.
Publicado: (2012)

Prenatal diagnosis of L1CAM gene mutations in X-linked hydrocephalus
por: Yamasaki, Mami, et al.
Publicado: (2006)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7j7ai3mbcv4tea3jd14jo9rgjp